Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature

Med Oncol. 2012 Dec;29(5):3416-20. doi: 10.1007/s12032-012-0285-x. Epub 2012 Jun 29.

Abstract

Cutaneous metastasation is a very rare manifestation of ovarian cancer. We present the case of a 64-year-old woman with recurrent platinum-refractory ovarian cancer and skin metastasis. The patient was treated with intraperitoneal catumaxomab due to massive refractory malignant ascites. Clinical response of the skin metastasis was observed during the intraperitoneal treatment with catumaxomab. Even though response of extraperitoneal tumor sites can be explained with intravascular uptake and a possible vaccination effect, this phenomenon has not been reported up to this point to the best of our knowledge.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma, Papillary / drug therapy*
  • Adenocarcinoma, Papillary / secondary*
  • Antibodies, Bispecific / administration & dosage*
  • Antineoplastic Agents / administration & dosage
  • Ascites / drug therapy
  • Ascites / etiology
  • Female
  • Humans
  • Immunotherapy / methods
  • Infusions, Parenteral
  • Middle Aged
  • Neoplasm Seeding
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / pathology*
  • Peritoneal Neoplasms / secondary
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / secondary*

Substances

  • Antibodies, Bispecific
  • Antineoplastic Agents
  • catumaxomab